---
title: "12 Health Care Stocks Moving In Thursday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302781094.md"
description: "During Thursday's after-market session, several healthcare stocks experienced significant volatility. Lucid Diagnostics surged 41.9% to $0.46, while Aardvark Therapeutics rose 19.74% to $4.73. Other gainers included Geovax Labs, NeuroOne Medical Tech, PAVmed, and Estrella Immunopharma. Conversely, Scinai Immunotherapeutics fell 7.7%, Artiva Biotherapeutics dropped 6.46%, and Longeveron declined 6.3%. Beyond Air, Elicio Therapeutics, and Valion Bio also saw decreases."
datetime: "2026-10-22T21:05:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302781094.md)
  - [en](https://longbridge.com/en/news/302781094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302781094.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's After-Market Session

### Gainers

-   **Lucid Diagnostics** (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million.
-   **Aardvark Therapeutics** (NASDAQ:AARD) stock increased by 19.74% to $4.73. The market value of their outstanding shares is at $85.3 million.
-   **Geovax Labs** (NASDAQ:GOVX) stock moved upwards by 8.13% to $0.23. The market value of their outstanding shares is at $1.1 million.
-   **NeuroOne Medical Tech** (NASDAQ:NMTC) shares moved upwards by 7.14% to $1.05. The company's market cap stands at $8.9 million.
-   **PAVmed** (NASDAQ:PAVM) stock rose 6.82% to $2.19. The company's market cap stands at $21.9 million.
-   **Estrella Immunopharma** (NASDAQ:ESLA) shares increased by 6.41% to $0.77. The company's market cap stands at $17.3 million.

### Losers

-   **Scinai Immunotherapeutics** (NASDAQ:SCNI) shares decreased by 7.7% to $0.56 during Thursday's after-market session.
-   **Artiva Biotherapeutics** (NASDAQ:ARTV) stock declined by 6.46% to $5.8. The company's market cap stands at $320.7 million.
-   **Longeveron** (NASDAQ:LGVN) shares declined by 6.3% to $1.49. The company's market cap stands at $4.7 million.
-   **Beyond Air** (NASDAQ:XAIR) stock declined by 5.83% to $2.1. The market value of their outstanding shares is at $2.1 million.
-   **Elicio Therapeutics** (NASDAQ:ELTX) stock declined by 5.16% to $1.84. The market value of their outstanding shares is at $41.2 million.
-   **Valion Bio** (NASDAQ:VBIO) stock declined by 4.83% to $0.91. The market value of their outstanding shares is at $1.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [AARD.US](https://longbridge.com/en/quote/AARD.US.md)
- [ARTV.US](https://longbridge.com/en/quote/ARTV.US.md)
- [ELTX.US](https://longbridge.com/en/quote/ELTX.US.md)
- [ESLA.US](https://longbridge.com/en/quote/ESLA.US.md)
- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)
- [LGVN.US](https://longbridge.com/en/quote/LGVN.US.md)
- [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md)
- [NMTC.US](https://longbridge.com/en/quote/NMTC.US.md)
- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)
- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)
- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)
- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)

## Related News & Research

- [Elicio Therapeutics' camupepimut misses primary endpoint in Phase 2 pancreatic cancer trial](https://longbridge.com/en/news/302883340.md)
- [Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient](https://longbridge.com/en/news/302906209.md)
- [PAVmed Subsidiary Lucid Diagnostics Completes Preferred Financing](https://longbridge.com/en/news/302784538.md)
- [FDA lifts clinical hold on Aardvark Therapeutics’ ARD-101 for Prader-Willi syndrome](https://longbridge.com/en/news/302772133.md)
- [Aardvark Therapeutics Publishes HERO and OLE Trial Data Presentation](https://longbridge.com/en/news/302899380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**